The Federal Court has found AFT Pharmaceuticals, makers of Maxigesic, have engaged in false and misleading conduct in contravention of the Australian Consumer Law when advertising Maxigesic.
The legal action was instigated by Reckitt Benckiser (RB), makers of Nuromol and following the Federal Court’s decision, a spokesperson for RB said: “Nuromol welcomes the decision by the Federal Court, which upholds the community’s expectation of the communication of fair, accurate and balanced information about over-the-counter medicines in Australia”.
The decision by the Federal Court confirms that the claims made by the makers of Maxigesic of superiority over any other paracetamol/ibuprofen combination including paracetamol or ibuprofen were not backed by reliable scientific evidence.
Claims made by the makers of Maxigesic that were found to be false and misleading included:
- Maxigesic provides stronger and more effective relief from all pain than Nuromol or any other paracetamol/ibuprofen combination.
- Maxigesic provides stronger and more effective relief from pain than OTC doses of either ibuprofen or paracetamol alone.